This article is more than 5 years old. Information may no longer be current.
Monoclonal antibodies show promise in treating solid tumors
Click Here to Manage Email Alerts
Tremendous excitement currently surrounds the use of immuno-oncology agents for the treatment of various of solid tumors.
Immuno-oncology treatments – including girentuximab (Rencarex, Wilex), atezolizumab (Tecentriq, Genentech) and durvalumab (MEDI4736, AstraZeneca) – have continued to demonstrate efficacy, however, one of the concerns surrounding these agents has been toxicity.
Recent results of a phase 1/ phase 2 first-in-human, open-label study has demonstrated that the use of durvalumab appeared safe and effective in patients with advanced urothelial bladder cancer.
A single-arm, phase 2 study has also demonstrated that the use of ofatumumab (Arzerra, Novartis) improved overall response rates in patients with Waldenström macroglobulinemia.
In addition, novel treatment advances have demonstrated that the use of anti–PD-1 antibodies may safely and effectively treat patients with advanced melanoma who have pre-existing autoimmune disorders or who experienced major toxicity with prior ipilimumab (Yervoy, Bristol-Myers Squibb) treatment.
This supplement, brought to you by HemOnc Today, offers the most up-to-date research on advances utilizing immunotherapies to treat solid tumors.
Click here to view the interactive pdf, and visit the Immuno-Oncology Resource Center for additional headlines on developments in and the use of immuno-oncology agents.
